Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Synthetic Vaccines in TNBC
NCT04105582Phase 1Completed
- Sponsor
- Universidad Nacional de Colombia
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neo-DCVac in triple-negative breast cancer (TNBC), sponsored by Universidad Nacional de Colombia. Primary endpoint: Adverse effects and Safety at 1 year. Started Aug 2019; status: completed.
02
Drugs
Neo-DCVac
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04105582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105582.